EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16

Shaobo Zhang, Yumeng Hu, Zhijun Zhou, Gaoyuan Lv, Chenze Zhang, Yuanyuan Guo, Fangxia Wang, Yuxin Ye, Haoran Qi, Hui Zhang, Wenming Wu, Min Li und 1 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci195970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Shaobo Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of M…. Hauptthemen laut MEDLINE: Zinc Finger E-box-Binding Homeobox 1, Pancreatic Neoplasms, Drug Resistance, Neoplasm, Chemokine CXCL16. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer (PC) is notoriously resistant to both chemotherapy and immunotherapy, presenting a major therapeutic challenge. Epigenetic modifications play a critical role in PC progression, yet their contribution to chemoimmunotherapy resistance remains poorly understood. Here, we identified the transcription factor ZEB1 as a critical driver of chemoimmunotherapy resistance in PC. ZEB1 knockdown synergized with gemcitabine and anti–PD-1 therapy, markedly suppressed PC growth, and prolonged survival in vivo. Single-cell and spatial transcriptomics revealed that ZEB1 ablation promoted tumor pyroptosis by recruiting and activating GZMA + CD8 + T cells in the tumor core through epigenetic upregulation of CXCL16 . Meanwhile, ZEB1 blockade attenuates CD44 + neutrophil–induced CD8 + T cell exhaustion by reducing tumor-derived SPP1 secretion, which otherwise promotes exhaustion through activation of the PD-L1/PD-1 pathway. Clinically, high ZEB1 expression correlated with chemoresistance, immunosuppression, and diminished CXCL16 levels in patients with PC. Importantly, the epigenetic inhibitor mocetinostat (targeting ZEB1) potentiated the efficacy of chemoimmunotherapy, including anti–PD-1 and CAR T therapies, in patient-derived organoids, xenografts, and orthotopic models. Our study unveils ZEB1 as a master epigenetic regulator of chemoimmunotherapy resistance and proposes its targeting as a transformative strategy for PC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zinc Finger E-box-Binding Homeobox 1Pancreatic NeoplasmsDrug Resistance, NeoplasmChemokine CXCL16ImmunotherapyDown-RegulationNeoplasm ProteinsHumansAnimalsMiceCell Line, TumorDeoxycytidineFemaleGemcitabineGene Expression Regulation, NeoplasticCD8-Positive T-LymphocytesProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

Cancer immunotherapyCell biologyEpigeneticsNeutrophilsOncology

Substanzen

Zinc Finger E-box-Binding Homeobox 1ZEB1 protein, humanChemokine CXCL16CXCL16 protein, humanDeoxycytidineNeoplasm ProteinsZEB1 protein, mouseGemcitabineProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Medicine and.
  • Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • National Key Laboratory of Efficacy and Mechanism on Chinese Medicine for Metabolic Diseases, Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
  • Department of Pathology and.
  • Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
  • Beijing Hope Run Special Fund of Cancer Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Zhang, S., Hu, Y., Zhou, Z., Lv, G., Zhang, C., Guo, Y., Wang, F., Ye, Y., Qi, H., Zhang, H., Wu, W., Li, M., & Liu, M. (2025). ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16. Journal of Clinical Investigation. https://doi.org/10.1172/jci195970

Vancouver

Zhang S, Hu Y, Zhou Z, Lv G, Zhang C, Guo Y, et al. ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16. Journal of Clinical Investigation. 2025. doi:10.1172/jci195970

BibTeX
@article{Zhang2025,
  author = {Zhang, Shaobo and Hu, Yumeng and Zhou, Zhijun and Lv, Gaoyuan and Zhang, Chenze and Guo, Yuanyuan and Wang, Fangxia and Ye, Yuxin and Qi, Haoran and Zhang, Hui and Wu, Wenming and Li, Min and Liu, Mingyang},
  title = {ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci195970}
}
Kostenlos starten →